Materials Literature
按标题、摘要、年份、主题和来源检索公开元数据。结果保留作者、摘要、分类与原始来源链接。
2D competitive systems shows a large variety of solid and aggregate patterns,\nre-entrant fluid phase, a continuous melting as predicted by the KTHNY theory\nand, in some cases, waterlike anomalies. In this paper, we employ Langevin\nDynamics simulations of a ramp-like core-softened fluid that have two\ncharacteristic…
J Biomed Mater Res A. 2020;108(4):839–850. doi:10.1002/jbm.a.36862 The author Dr. Mohsen Alipour's affiliation was earlier published as. 1- Department of Advanced Medical Sciences and Technologies, School of Medicine, Jahrom University of Medical Sciences (JUMS), Jahrom, Iran. 2- Department of Nano Biotechnology, Facu…
It was theoretically predicted more than 20 years ago [A.G. Lebed and K. Yamaji, {\it Phys. Rev. Lett.} {\bf80}, 2697 (1998)] that a triplet quasi-two-dimensional (Q2D) superconductor could restore its superconducting state in parallel magnetic fields, which are higher than its upper critical magnetic field, $H > H_{c…
Abstract Combinatorial regimen are a mainstay in oncology. Taxanes and trastuzumab are both gold standards for HER2 positive breast cancer. To what extent they could reshape tumor micro-environment remains to be elucidated. The aim of this study was to compare in breast cancer mice models the antiproliferative efficac…
Abstract Pancreatic cancer is the third most common cause of death from cancer in the US. The disease has a poor prognosis with a five-year survival rate under 10%. Mutations in KRAS are driving tumor growth in about 95% of patients with pancreatic cancer. Currently there are no approved drugs that target KRAS. Recent…
Abstract Background: Monalizumab (IPH2201) is a humanized IgG4 monoclonal antibody that targets NKG2a, resulting in suppression of inhibitory signaling by tumors on NK cells. We aimed to develop a population pharmacokinetics (PK) model of monalizumab and to identify and quantitate the impact of patient/disease charact…
Abstract Background: Immunotherapy has become a powerful strategy for cancer treatment. Immunomodulators such as cytokines (e.g. IL-2) and engineered antibody fragments (e.g. bispecific diabodies) can induce anti-tumor immune responses, but their clinical applications are limited by the unfavorable pharmacokinetic pro…
Abstract Background: Acute myeloid leukemia (AML) is a hematological malignant tumor. The common chemotherapy results in various side-effect and drug-resistance for AML, so it is urgent to find a non-toxic natural drug for AML therapy. Herein, for the first time, the Se nanoparticles embedded in nanotube consisted of…
Abstract One of the major challenges in colon cancer chemotherapy is multidrug resistance (MDR), which is typically mediated by the overexpression of ATP-binding cassette (ABC) transporters, particularly P-glycoprotein (P-gp, ABCB1, MDR1). A number of P-gp inhibitors have been developed, however, none of these compoun…
Abstract Introduction; Tumor Treating Fields (TTFields) is a novel non-invasive anticancer treatment modality utilizing alternating electric fields. TTFields is FDA approved for glioblastoma patients after demonstrating a 5 months increase in overall survival, and for unresectable mesothelioma patients after the STELL…
Abstract Current cancer therapy relies on the use of cytotoxic agents (‘chemotherapy') that was developed over 50 years ago. These agents are very effective, but efficacy is limited by off-target toxicity to normal tissues. It is widely recognized that chemotherapy could be far more effective if higher doses could be…
Understanding how light interacts at the nanoscale with metals, semiconductors, or ordinary dielectrics is pivotal if one is to properly engineer nano-antennas, filters and, more generally, devices that aim to harness the effects of new physical phenomena that manifest themselves at the nanoscale. We presently report…
Abstract Dual Bcl-2/Bcl-xL inhibitors are expected to deliver therapeutic benefit in many hematological and solid tumors, but their clinical application has been limited by tolerability issues, including thrombocytopenia. AZD4320, a potent dual Bcl-2/Bcl-xL inhibitor, showed good efficacy but encountered dose limiting…
Abstract To avoid the narrow therapeutic window and take advantage of the anticancer efficacy of triptolide (TP), a major active component of Tripterygium wilfordii Hook.F., a novel thermo-responsive nano-micelle hydrogel was fabricated in present study for the sustained release of TP in breast tumor tissue. Briefly,…
Abstract The cytokine interleukin-2 (IL-2) is an endogenous agonist of the IL-2 pathway that activates and expands tumor killing lymphocytes. High doses of IL-2 are needed to activate CD8 T cells and NK cells, through binding on low-affinity IL-2 receptor beta gamma subunits (IL-2Rβγ). Severe toxic side effects associ…
Abstract Background: IMpower133 (NCT02763579), a global Phase I/III, randomized, double-blind, placebo (PBO)-controlled trial, showed that the addition of atezo (anti-PD-L1) to CE for 1L ES-SCLC led to statistically and clinically significant OS and PFS improvement vs CE alone. Here we report updated OS and explorator…
Abstract Background MCL-1 is an important anti-death BCL-2 family protein and plays a key role in blocking apoptosis in cancer cells. MCL-1 gene is located in one of the most frequently amplified locus in various hematologic malignancies and solid tumors, including prostate, lung, pancreatic, breast, ovarian and cervi…
Abstract Reactive oxygen species (ROS) regulates the proliferation of human immunodeficiency virus (HIV-1) and Mycobacterium tuberculosis ( Mtb ) inside the infected immune cells. However, the application of this knowledge to develop therapeutic strategies remained unsuccessful due to unfavorable consequences of manip…
Abstract Introduction: The rapid growth of research into immuno-oncology research has fueled a need to be able to evaluate the efficacy of immunotherapies in a timely and comprehensive fashion. However, established non-invasive imaging approaches have been insufficient to meet all requirements. Magnetic Particle Imagi…
Abstract Introduction: Although a number of effective drugs are available to treat central nervous system (CNS) disorders, their ability to breach the tight regulation of the blood brain barrier (BBB) still remains a major challenge. Recently, the use of tumor treating fields (TTFields) has become an effective treatme…